PL2709986T3 - Deuterowane pochodne iwakaftoru - Google Patents

Deuterowane pochodne iwakaftoru

Info

Publication number
PL2709986T3
PL2709986T3 PL12725197T PL12725197T PL2709986T3 PL 2709986 T3 PL2709986 T3 PL 2709986T3 PL 12725197 T PL12725197 T PL 12725197T PL 12725197 T PL12725197 T PL 12725197T PL 2709986 T3 PL2709986 T3 PL 2709986T3
Authority
PL
Poland
Prior art keywords
ivacaftor
deuterated derivatives
deuterated
derivatives
Prior art date
Application number
PL12725197T
Other languages
English (en)
Inventor
Adam J. Morgan
Original Assignee
Concert Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc. filed Critical Concert Pharmaceuticals Inc.
Publication of PL2709986T3 publication Critical patent/PL2709986T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL12725197T 2011-05-18 2012-05-17 Deuterowane pochodne iwakaftoru PL2709986T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161487497P 2011-05-18 2011-05-18

Publications (1)

Publication Number Publication Date
PL2709986T3 true PL2709986T3 (pl) 2017-09-29

Family

ID=46201810

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12725197T PL2709986T3 (pl) 2011-05-18 2012-05-17 Deuterowane pochodne iwakaftoru
PL17160386T PL3235812T3 (pl) 2011-05-18 2012-05-17 Deuterowane pochodne iwakaftoru

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17160386T PL3235812T3 (pl) 2011-05-18 2012-05-17 Deuterowane pochodne iwakaftoru

Country Status (20)

Country Link
EP (2) EP3235812B1 (pl)
JP (2) JP6063455B2 (pl)
AU (5) AU2012255711B2 (pl)
BR (1) BR112013029240B1 (pl)
CA (1) CA2834574C (pl)
CY (2) CY1119090T1 (pl)
DK (2) DK2709986T3 (pl)
EA (1) EA028378B1 (pl)
ES (2) ES2628465T3 (pl)
HR (2) HRP20170754T1 (pl)
HU (1) HUE032771T2 (pl)
LT (1) LT2709986T (pl)
ME (2) ME03652B (pl)
MX (1) MX349159B (pl)
PL (2) PL2709986T3 (pl)
PT (2) PT3235812T (pl)
RS (2) RS59744B1 (pl)
SI (2) SI2709986T1 (pl)
SM (2) SMT201900679T1 (pl)
WO (1) WO2012158885A1 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
PL2709986T3 (pl) * 2011-05-18 2017-09-29 Concert Pharmaceuticals Inc. Deuterowane pochodne iwakaftoru
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 薬学的組成物およびその投与
CN104619321A (zh) * 2012-04-06 2015-05-13 Uab研究基金会 用于增加cftr活性的方法
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたcftr増強物質
WO2014078842A1 (en) * 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
US20180353500A1 (en) * 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
MA42954A (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals Europe Ltd Potentialisateurs cftr deutérés
BR112018070747B1 (pt) * 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
MA49235B1 (fr) 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたcftr増強物質
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
SG11202004264VA (en) * 2017-12-01 2020-06-29 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ (ヨーロッパ) リミテッド 重水素化されたcftr増強物質
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
MX2022001827A (es) 2019-08-14 2022-06-09 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
EP3970718A1 (en) 2020-09-18 2022-03-23 Charité - Universitätsmedizin Berlin New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
EP4225750A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225737A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076618A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en) 2020-10-07 2023-11-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225748A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CR20230198A (es) 2020-10-07 2023-07-03 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022076626A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230374038A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN116670143A (zh) 2020-10-07 2023-08-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
TW202233635A (zh) 2020-10-07 2022-09-01 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
JP2025506382A (ja) 2022-02-03 2025-03-11 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
KR20240155228A (ko) 2022-02-03 2024-10-28 버텍스 파마슈티칼스 인코포레이티드 (6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
AU2023218262A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20250008540A (ko) 2022-04-06 2025-01-14 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막관통 전도도 조절자의 조절제
US20250340568A1 (en) 2022-05-16 2025-11-06 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
CA3253026A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated TREATMENT METHODS FOR CYSTIC FIBROSIS
WO2025076240A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cystic fibrosis transmembrane conductance regulator
WO2025076235A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2025166342A1 (en) 2024-02-04 2025-08-07 Vertex Pharmaceuticals Incorporated Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis
EP4648753B1 (en) 2024-02-07 2026-02-18 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
MX341797B (es) * 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
BRPI0516170A (pt) 2004-09-29 2008-08-26 Cordis Corp formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
EP1974212A1 (en) 2005-12-27 2008-10-01 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
AU2008299921B2 (en) * 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
LT3345625T (lt) 2008-08-13 2021-02-10 Vertex Pharmaceuticals Incorporated Farmacinė kompozicija ir jos vartojimas
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
PL2709986T3 (pl) * 2011-05-18 2017-09-29 Concert Pharmaceuticals Inc. Deuterowane pochodne iwakaftoru

Also Published As

Publication number Publication date
SMT201900679T1 (it) 2020-01-14
LT2709986T (lt) 2017-05-25
PT3235812T (pt) 2019-12-09
EA028378B1 (ru) 2017-11-30
BR112013029240A2 (pt) 2017-01-31
EP3235812B1 (en) 2019-09-04
ES2628465T3 (es) 2017-08-02
CA2834574A1 (en) 2012-11-22
HUE032771T2 (en) 2017-10-30
CY1122498T1 (el) 2021-01-27
ES2758028T3 (es) 2020-05-04
ME03652B (me) 2020-07-20
AU2012255711B2 (en) 2017-05-04
AU2021203786B2 (en) 2023-03-16
DK3235812T3 (da) 2019-11-25
AU2017208313A1 (en) 2017-08-17
HK1244183A1 (en) 2018-08-03
AU2021200970A1 (en) 2021-03-11
EP2709986B1 (en) 2017-03-22
SI3235812T1 (sl) 2020-02-28
EP2709986A1 (en) 2014-03-26
EA201391615A1 (ru) 2014-03-31
EP3235812A1 (en) 2017-10-25
AU2019222862B2 (en) 2021-03-11
HRP20192114T1 (hr) 2020-02-21
RS59744B1 (sr) 2020-02-28
DK2709986T3 (en) 2017-05-08
AU2019222862A1 (en) 2019-09-19
AU2021203786A1 (en) 2021-07-08
HRP20170754T1 (hr) 2017-07-28
PT2709986T (pt) 2017-06-26
PL3235812T3 (pl) 2020-04-30
JP6063455B2 (ja) 2017-01-18
BR112013029240B1 (pt) 2023-05-16
JP2017078082A (ja) 2017-04-27
MX349159B (es) 2017-07-14
SMT201700302T1 (it) 2017-07-18
ME02749B (me) 2018-01-20
AU2021200970B2 (en) 2022-07-14
WO2012158885A1 (en) 2012-11-22
SI2709986T1 (sl) 2017-07-31
CY1119090T1 (el) 2018-01-10
RS56096B1 (sr) 2017-10-31
JP2014515351A (ja) 2014-06-30
CA2834574C (en) 2019-09-17
MX2013013450A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
HUE047354T2 (hu) Ivacaftor deuterizált származékai
PL2709986T3 (pl) Deuterowane pochodne iwakaftoru
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
SG10201601802YA (en) Dispiropyrrolidine derivatives
EP2756410A4 (en) GEOMIGRATION OF USER STATUS
IL231229A0 (en) New history of dihydroquinoline-2-one
IL233081A (en) History of Batolin
SG11201401937YA (en) New aryl-quinoline derivatives
IL247639B (en) History of heteroaryl piperidine
IL233001A0 (en) New iso-ergoline histories
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
SI2766342T1 (sl) Derivati fenil-gvanidina
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
IL230977A (en) A crystalline form of relapaldib
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
IL231452A0 (en) Amorphous form of dolutegravir
ZA201209319B (en) Cyclopropyl-indole derivatives
PH32011000651S1 (en) Piece of jewellery
PH32011000650S1 (en) Piece of jewellery
PH32011000649S1 (en) Piece of jewellery
PH32011000648S1 (en) Piece of jewellery